fig3

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance

Figure 3. Gene Expression Levels for Tyrosine Kinases in Leukemic Cells from Adult Patients with KMT2A/MLL-R+ B-ALL vs. Other Types of B-ALL without KMT2A/MLL Rearrangements. Probeset level normalized signal values from the archived data set GSE13159 were examined in these comparisons. The cluster figure displays the expression levels in KMT2A/MLL-R+ ALL cells mean centered to the reference group (other types of ALL without KMT2A/MLL Rearrangements) represented by log2-transformed fold change values (blue to red color indicates under-expression to over-expression respectively in KMT2A/MLL-R+ samples). Co-regulated probesets are organized and depicted by dendrograms for both probesets (rows) and patients (columns). The comparison of the log2-transformed RMA values for leukemic cells from 70 adult patients with KMT2A/MLL-R+ ALL with the RMA values for leukemic cells from 131 adult patients with other forms of ALL resulted in 25 probesets that were significantly dysregulated, of which 10 were upregulated in KMT2A/MLL-R+ subset of cases. FLT3_206674_at was the most significantly upregulated probeset (Fold Change = 5.69; P-value < 10-8) followed by BLK_206255_at (Fold Change = 3.95; P-value < 10-8) and HCK_208018_s_at (Fold Change = 2.21; P-value < 10-8) [Supplementary Table 6]. FLT3 was co-regulated with BLK (2 probesets), HCK and LYN (3 probesets).

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/